• 咨询热线
    客服服务热线 13671568941/15317326293
  • 在线咨询
  • 微信客服
    微信客服
  • 公众号
    扫码关注公众号

PDE9-IN-1

CAS No. 2305087-92-5

PDE9-IN-1 ( —— )

产品货号. M26362 CAS No. 2305087-92-5

PDE9-IN-1 is a potent, selective, and orally bioavailable Inhibitor of phosphodiesterase-9A (PDE9A)(IC50 of 8.7 nM).

纯度: >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
规格 价格/人民币 库存 数量
5MG ¥1847 有现货
10MG ¥2876 有现货
25MG ¥4779 有现货
50MG ¥6958 有现货
100MG ¥9558 有现货
500MG ¥19197 有现货
1G 获取报价 有现货

生物学信息

  • 产品名称
    PDE9-IN-1
  • 注意事项
    本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
  • 产品简述
    PDE9-IN-1 is a potent, selective, and orally bioavailable Inhibitor of phosphodiesterase-9A (PDE9A)(IC50 of 8.7 nM).
  • 产品描述
    PDE9-IN-1 is a potent, selective, and orally bioavailable Inhibitor of phosphodiesterase-9A (PDE9A)(IC50 of 8.7 nM).(In Vivo):In the Unilateral common carotid artery occlusion (UCCAO) mouse model, PDE9-IN-1 (2.5-5.0 mg/kg; orally) significantly reduces the day 6 escape latency time, increases the frequency of platform area crossings, and recoveres learning and memory function. High dose group possibly improved the escape latency time of mice.
  • 同义词
    ——
  • 通路
    Others
  • 靶点
    Other Targets
  • 受体
    NMDA receptor
  • 研究领域
    ——
  • 适应症
    ——

化学信息

  • CAS Number
    2305087-92-5
  • 分子量
    362.4
  • 分子式
    C17H23FN6O2
  • 纯度
    >98% (HPLC)
  • 溶解度
    ——
  • SMILES
    C[C@@H](Nc1nc2n(ncc2c(=O)[nH]1)C1CCCC1)C(=O)N1CC[C@H](F)C1
  • 化学全称
    ——

运输与储存

  • 储存条件
    (-20℃)
  • 运输条件
    With Ice Pack
  • 稳定性
    ≥ 2 years

参考文献

1.Lozovaya N, Gataullina S, et al. Selective suppression of excessive GluN2C expression rescues early epilepsy in a tuberous sclerosis murine model. Nat Commun. 2014 Aug 1;5:4563.
产品手册
关联产品
  • Carbazochrome sodium...

    Carbazochrome sodium sulfonate (AC-17) is an antihemorrhagic for use in the treatment of hemorrhoids.

  • Diosmin Impurity 8

    Diosmin analog. Reference standards.

  • (-)-Carvone

    (-)-Carvone is a natural product which probably has antioxidant and anti-inflammatory capabilities.